




The relative strengths and weaknesses of Nexvet Biopharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nexvet Biopharma plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Nexvet Biopharma plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 319%, being 65% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	33,088
Cost of Goods Sold	0
Intangible Assets	2.0
Liabilities, Current	3,197
Liabilities, Non-Current	5,538
Other Assets	0
Other Compr. Net Income	302
Other Expenses	0
Other Liabilities	0
Other Net Income	-334
Other Revenues	3,667
Property and Equipment	514
Research and Development	5,617
Selling, General and Administrative Expense	4,426

Output Variable	Value in 1000 USD
Assets	33,604
Liabilities	8,735
Expenses	10,043
Revenues	3,667
Stockholders Equity	24,869
Net Income	-6,710
Comprehensive Net Income	-6,559
BaseVar	28,342
ECR before LimitedLiability	225%
Economic Capital Ratio	319%